We are developing a novel vaccination approach to prepare for future emerging epidemics or pandemics caused by flaviviruses.
The project encompasses the entire value chain from basic science research institutions to private companies. The involvement of a vaccine developer and other key stakeholders will ensure the seamless transition of the vaccine candidate from pre-clinical investigation to clinical development. As illustrated below, the phases leading to commercialisation are:
Through the design of comprehensive to-market strategies, strategic patenting, and collaboration with potential investors, Flavivaccine aims to start clinical evaluation right after the end of the project and to deliver a broad-spectrum flavivirus vaccine solution to populations worldwide at risk of mosquito-borne flavivirus infections.
The project will ultimately offer a global opportunity by protecting individuals worldwide against a broad range of flaviviruses including but not limited to dengue, yellow fever, Zika and West Nile viruses, and a multi-market potential, as both a travel vaccine, protective vaccine in endemic areas and pandemic response strategy.
